Oncotarget

Research Papers:

The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells

Giorgia Giordani, Marilena Barraco, Angela Giangrande, Giovanni Martinelli, Viviana Guadagnuolo, Giorgia Simonetti, Giovanni Perini and Roberto Bernardoni _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:55313-55327. https://doi.org/10.18632/oncotarget.10879

Metrics: PDF 1389 views  |   HTML 1767 views  |   ?  


Abstract

Giorgia Giordani1,5,*, Marilena Barraco1,6,*, Angela Giangrande2, Giovanni Martinelli3, Viviana Guadagnuolo3, Giorgia Simonetti3, Giovanni Perini1,4, Roberto Bernardoni1,4

1Department of Pharmacy and Biotechnology (FaBiT), University of Bologna, Bologna, Italy

2Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP 67404 Illkirch, France

3Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy

4Health Sciences and Technology - Interdepartmental Center for Industrial Research (HST-ICIR), University of Bologna, Ozzano Emilia, Italy

5Present address: Department of Biological Sciences, School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield, UK

6Present address: Institute of Hematology, “L e A Seràgnoli”, S. Orsola-Malpighi Hospital, Bologna, Italy

*These authors contributed equally to this work

Correspondence to:

Roberto Bernardoni, email: roberto.bernardoni@unibo.it

Giovanni Perini, email: giovanni.perini@unibo.it

Keywords: PF-04449913, Smoothened inhibitor, leukemia, Drosophila, prohemocytes

Received: December 09, 2015     Accepted: June 26, 2016     Published: July 28, 2016

ABSTRACT

The efficient treatment of hematological malignancies as Acute Myeloid Leukemia, myelofibrosis and Chronic Myeloid Leukemia, requires the elimination of cancer-initiating cells and the prevention of disease relapse through targeting pathways that stimulate generation and maintenance of these cells. In mammals, inhibition of Smoothened, the key mediator of the Hedgehog signaling pathway, reduces Chronic Myeloid Leukemia progression and propagation. These findings make Smo a candidate target to inhibit maintenance of leukemia-initiating cells. In Drosophila melanogaster the same pathway maintains the hematopoietic precursor cells of the lymph gland, the hematopoietic organ that develops in the larva. Using Drosophila as an in vivo model, we investigated the mode of action of PF-04449913, a small-molecule inhibitor of the human Smo protein. Drosophila larvae fed with PF-04449913 showed traits of altered hematopoietic homeostasis. These include the development of melanotic nodules, increase of circulating hemocytes, the size increase of the lymph gland and accelerated differentiation of blood cells likely due to the exit of multi-potent precursors from quiescence. Importantly, the Smo inhibition can lead to the complete loss of hematopoietic precursors. We conclude that PF-04449913 inhibits Drosophila Smo blocking the Hh signaling pathway and causing the loss of hematopoietic precursor cells. Interestingly, this is the effect expected in patients treated with PF-04449913: number decrease of cancer initiating cells in the bone marrow to reduce the risk of leukemia relapse. Altogether our results indicate that Drosophila comprises a model system for the in vivo study of molecules that target evolutionary conserved pathways implicated in human hematological malignancies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10879